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The filoviruses Marburg virus and Ebola virus (EBOV) quickly outpace host immune responses and cause hemorrhagic
fever, resulting in case fatality rates as high as 90% in humans and nearly 100% in nonhuman primates. The
development of an effective therapeutic for EBOV is a daunting public health challenge and is hampered by a paucity
of knowledge regarding filovirus pathogenesis. This report describes a successful strategy for interfering with EBOV
infection using antisense phosphorodiamidate morpholino oligomers (PMOs). A combination of EBOV-specific PMOs
targeting sequences of viral mRNAs for the viral proteins (VPs) VP24, VP35, and RNA polymerase L protected rodents in
both pre- and post-exposure therapeutic regimens. In a prophylactic proof-of-principal trial, the PMOs also protected
75% of rhesus macaques from lethal EBOV infection. The work described here may contribute to development of
designer, ‘‘druggable’’ countermeasures for filoviruses and other microbial pathogens.
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Introduction
The development of effective countermeasures to the
ﬁloviruses Ebola virus (EBOV) and Marburg virus (MARV)
has been a long-sought and difﬁcult endeavor, yielding little
success [1,2]. Although the worst outbreaks have resulted in
only several hundred deaths worldwide [3–6], the ﬁloviruses
are considered a signiﬁcant global health threat, because as
the reservoir remains unknown, the pathogen is extremely
deadly and highly infectious by aerosol, and there is
anecdotal evidence that the use of both MARV and EBOV
were explored as potential biowarfare agents in the offensive
program of the former Soviet Union [7–10]. The ﬁloviruses
are relatively simple viruses of 19-Kb genomes and consist of
seven genes which encode nucleoprotein (NP), glycoprotein,
four smaller viral proteins (VPs) (VP24, VP30, VP35, and
VP40), and the RNA-dependent RNA polymerase (L protein),
all in a single strand of negative-sensed RNA [11].
The development of an effective treatment for EBOV is
hindered by lack of a clear understanding of ﬁlovirus
pathogenesis, disparity between animal models, and both
the difﬁculty and danger of working with EBOV under
biosafety–level-4 conditions [1,2]. Although there has been
signiﬁcant progress toward vaccine development via demon-
stration of protection in nonhuman primates from EBOV
illness and death [12,13], a vaccine will not fulﬁll all
requirements for EBOV countermeasures. Administration
of type I interferons, therapeutic vaccines, immune globulins,
ribavirin, and other nucleoside analogues have been some-
what successful in rodent EBOV models, but all failed to
beneﬁt EBOV-infected nonhuman primates [1,14,15]. EBOV
frequently causes severe disseminated intravascular coagu-
lation, and administration of a recombinant clotting inhib-
itor was recently shown to protect 33% of rhesus monkeys
[16]. It appears that host-directed consequence management
of the disease alone may not be sufﬁcient, and an additional
well-orchestrated sequence-speciﬁc attack on viral replica-
tion may be more effective as a successful anti-ﬁlovirus
treatment regimen.
The ability of virus-speciﬁc antisense oligonucleotides to
inhibit viral growth by interfering with translation of viral
RNAs was ﬁrst demonstrated in 1978 [17,18]. Since then,
remarkable progress has been made by modifying oligonu-
cleotides to increase their stability, afﬁnity, and delivery into
cells [19]. Phosphorodiamidate morpholino oligomers (PMOs)
are a subclass of antisense agents modiﬁed to include a
phosphorodiamidate linkage and morpholine ring, and
exhibit limited off-target effects, favorable base stacking,
high duplex stability, high solubility, cell permeability, and no
hybridization complexities [20,21]. Formation of a PMO:mR-
NA duplex can effectively block translation of viral RNA,
thereby inhibiting viral replication [22,23]. Antisense PMO
are effective as antivirals against vesiviruses [24], ﬂaviviruses
[23,25], and the SARS coronavirus [26]. The successful
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demonstrated in vitro, but has not yet been shown in an
animal model.
Results
In Vitro Inhibition of EBOV Translation and Replication by
Gene-Specific PMOs
We hypothesized that PMO inhibition of viral mRNA
translation would provide protection against EBOV infec-
tions. In order to test our hypothesis, PMOs were designed to
inhibit translation of the mRNAs for EBOV VP35, VP24, and
L (Figure 1A). These EBOV-speciﬁc PMOs demonstrated
sequence-speciﬁc inhibition when compared with a PMO
molecule with a MARV-speciﬁc sequence or PMOs containing
EBOV-scrambled sequences in a reporter-based in vitro
translation assay (Figure 1B–1D). No inhibition was observed
for the scrambled or nonspeciﬁc PMO at up to 10 lM
concentration for the EBOV VP24, VP35, or L RNA targets
(Figure 1B–1D). To determine whether the EBOV-speciﬁc
PMOs could reduce viral propagation in vitro, VeroE6 cells
were pretreated with the PMOs at a concentration of 20 lM
and then infected with a multiplicity of infection of 1.
Treatment with the EBOV VP24-, VP35-, or L-speciﬁc PMO
was able to consistently reduce the viral titers in the EBOV-
infected VeroE6 cells (Figure 1E). A combination of the three
PMOs also reduced the viral titers in the VeroE6 cells, but did
not show an enhanced effect as compared with treatment
with any one of the PMOs (Figure 1E). In the same assay, the
viral titers in the scrambled PMO-treated cells were nearly
identical to those observed in untreated VeroE6 cells, and the
PMOs did not cause obvious cytotoxicity at concentrations
used in this assay (unpublished data).
EBOV-Specific PMOs Protect Rodents against Lethal EBOV
Infection
To evaluate the in vivo efﬁcacy of the EBOV-speciﬁc PMOs,
we ﬁrst determined the survival of mice treated with
individual PMOs at 24 h and 4 h before challenge with
1,000 plaque-forming units (pfu) of mouse-adapted EBOV.
The three PMOs exhibited a wide range of efﬁcacy against
lethal EBOV infection. Both the VP24- and VP35-speciﬁc
PMOs provided nearly complete protection when the mice
were pretreated twice with 500 lg doses (Figure 2A–2B, p ,
0.001 for both VP24 and VP35 PMO treatment versus PBS
treatment). In contrast, and despite its strong activity in the
cell-free translation assay, the L-speciﬁc PMO conferred
survival to ;30% of treated mice at the 500-lg dose (Figure
2C, p ¼0.5 for both doses of the L PMO compared with PBS-
treated mice). As expected, treatment of the mice with a
Marburg-speciﬁc VP24, VP35, or L PMO did not provide
protection against EBOV (Figure 2A–2C). Next, we inves-
tigated whether a combination of all these PMOs could
further enhance efﬁcacy. We found that when the VP24-,
VP35-, and L-speciﬁc PMOs were administered together at 24
h and 4 h before lethal EBOV challenge, this resulted in
robust protection at all the doses tested (Figure 2D, p ¼
0.00001, 0.001, and 0.0136, respectively, for the 500-, 50-, and
5-lg EBOV-speciﬁc PMO-treated mice compared with the
PBS-treated mice). To investigate the usefulness of the PMO
in a post-exposure regimen, mice were treated with a single
dose of the three PMOs administered 24 h after EBOV
infection (Figure 2E). The PMO-treated EBOV-infected mice
were fully protected at the 500-lg doses, and at lower doses
the post-challenge treatment provided enhanced protection
(p¼0.00001, 0.0136, and 0.2105, respectively, for the 500-, 50-,
and 5-lg PMO-treated mice compared with the PBS-treated
mice). Mice receiving a single PMO treatment 4 h before
infection showed similar protection (p ¼ 0.00001, 0.237, and
1.0, respectively, for the 500-, 50-, and 5-lg PMO-treated mice
compared with the PBS-treated mice). Here, a single dose of
PMO at 24 hpi was used and, at the highest concentration, the
combination of PMOs completely protected EBOV-infected
mice. In this single-dose therapeutic regimen, the lower PMO
dosages did not provide complete protection. It may be
possible that repeated injections of lower concentrations of
EBOV-speciﬁc PMOs could provide equivalent protection to
fewer administrations of higher amounts. Importantly, multi-
ple injections (n . 5) of nonspeciﬁc PMOs did not enhance
survival of EBOV-infected rodents (unpublished data).
Examination of tissues 3 d after infection showed that
treatment of mice with the combination of EBOV-speciﬁc
PMOs slowed viral spread compared to mice treated with the
scrambled PMO. Infected cells were easily observed in the
spleens of the mice treated with the scrambled PMO (Figure
3A), whereas few EBOV-infected cells could be found in the
spleens of the anti-EBOV PMO-treated mice (Figure 3B). By 6
d after viral inoculation, EBOV infection was fulminant in the
spleens of both EBOV and scrambled PMO-treated animals
(unpublished data) and had spread to the livers of both mice
treated with scrambled and combination PMOs (Figure 3C–
3D). However, the extent of the infection was limited in the
EBOV-speciﬁc combination PMO-treated mice, and, unlike
the scrambled PMO-treated mice, EBOV antigen was not
detectable within hepatocytes (Figure 3C–3D). Viral antigen
was not observed in the kidney on day 3; however, on day 6,
viral antigen was more readily observed in the kidneys of the
scrambled PMO-treated compared with the combination
PMO-treated mice (unpublished data). Further, the viral
titers in the spleen, liver, and kidney of the PMO-treated,
PLoS Pathogens | www.plospathogens.org January 2006 | Volume 2 | Issue 1 | e1 0006
Antisense Treatment for Ebola Virus
Synopsis
Ebola virus (EBOV) causes a highly lethal hemorrhagic fever that
results in up to 50%–90% mortality in humans. There are currently
no available vaccines or therapeutics to treat EBOV infection. To
date, multiple pre- and post-exposure therapeutic strategies,
primarily focused on bolstering the host immune response or
inhibiting viral replication, have been undertaken with limited
success. Here, Bavari and colleagues report the development of a
successful therapeutic regimen for EBOV infection based on
antisense phosphorodiamidate morpholino oligomers (PMOs).
PMOs are a subclass of chemically modified antisense oligonucleo-
tides that interfere with the translation of viral mRNA, thus inhibiting
viral amplification. Using a cell-free translation system, a cell-based
assay, and survival studies in rodents, we identified several
efficacious EBOV-specific PMOs. Further, prophylactic administration
of a combination of three EBOV-specific PMOs specifically targeting
VP24, VP35, and the viral polymerase L protected rhesus macaques
from lethal EBOV infection. This is the first successful antiviral
intervention against filoviruses in nonhuman primates. These
findings may serve as the basis for a new strategy to quickly
develop virus-specific therapies in defense against known, emerg-
ing, and genetically engineered bioterrorism threats.infected animals corroborated the observed pattern of
antigen staining within the tissues (Figure 3E).
To determine whether mice treated with the PMOs
generated immune responses to EBOV, they were tested for
EBOV-speciﬁc cell-mediated and humoral immune re-
sponses. 4 wk after infection, the mice demonstrated both
CD4
þ and CD8
þ T cell responses to multiple EBOV-speciﬁc
peptides, including NP and VP35 sequences (Figure 4A,
unpublished data). They also generated strong serum EBOV-
speciﬁc antibody responses that were similar to the post-
challenge antibody responses of mice protected by a
therapeutic vaccine containing Ebola virus-like particles
(Figure 4B) [15]. To ﬁnd out if the generated immune
responses were protective, PMO-treated mice were rechal-
lenged with another dose of 1,000 pfu of EBOV 4 wk after
surviving the initial challenge, and all the mice were
completely protected from the second lethal EBOV infection
(Figure 4C, p , 0.000001).
To verify the effectiveness of the PMO treatment in
another EBOV animal model, we infected guinea pigs with
EBOV and treated them with a single dose of the PMO
combination either 24 h before or 24 h or 96 h after EBOV
infection (Figure 5A). Survival was greatly increased in guinea
pigs receiving the treatment 96 h after EBOV infection (p ¼
0.029, compared with untreated guinea pigs), in contrast to
guinea pigs treated 24 h before or after infection (p¼0.5 and
0.227, respectively, compared with untreated guinea pigs).
The mean viral titer for each group, measured on 7 dpi,
closely mirrored the survival rates observed (Figure 5B).
Results of a logistic regression indicated that reduction of the
viral titer had a signiﬁcant effect on the survival outcome of
PMO-treated guinea pigs (p ¼ 0.0292). With each log10
reduction in viral titer, there was a 56% decrease in the odds
of surviving challenge (odds ratio ¼ 0.434). It remains to be
determined if administration of multiple or larger PMO
Figure 1. Gene-Specific PMOs Inhibit Ebola Virus Gene Translation and Growth
(A) Schematic diagram of the EBOV genome showing the PMO sequences and the relative locations of their mRNA targets.
(B–D) Sequence-specific inhibition of EBOV VP24 (B), VP35 (C), and L (D) gene targets in cell-free translation assay. Plasmids containing 150 nucleotides
encompassing the PMO target area from EBOV VP24, VP35, or L fused to firefly luciferase were used to generate RNA. Inhibition of the VP24, VP35, or L
RNA targets was assessed using in vitro translation reactions containing different concentrations of PMO targeting EBOV ( ) or MARV (&) VP24, VP35, or
L, respectively, or a scrambled (m) PMO, along with the respective RNA. The data are shown as means of three replicates per data point and the
standard error of the mean.
(E) Inhibition of viral amplification by PMOs in vitro. Vero E6 cells were pretreated for 24 h with 20 lM of EBOV VP24-specific PMO (blue), EBOV VP35-
specific PMO (red), EBOV L-specific PMO (yellow), combination of the three EBOV-specific PMOs (gray), or a scrambled PMO (black). The cells were
infected with EBOV-Zaire (multiplicity of infection¼ 1), and the viral titers were assessed at 24, 48, and 72 h post infection. The data are presented as
percent reduction of EBOV-specific PMO-treated cells, as compared with the scrambled PMO-treated cells (titers at 24 h were 127 pfu/ml, at 48 h were
4,241 pfu/ml, and at 72 h were 202,000 pfu/ml). The experiments were performed at least three times and a single representative experiment is shown.
DOI: 10.1371/journal.ppat.0020001.g001
PLoS Pathogens | www.plospathogens.org January 2006 | Volume 2 | Issue 1 | e1 0007
Antisense Treatment for Ebola Virusdoses might have increased the efﬁcacy of the PMO treat-
ments in the guinea pigs.
PMO Pretreatment Protects Rhesus Monkeys
Based on the encouraging results both in vitro and in
rodents, we designed a small proof-of-concept trial in
nonhuman primates. Rhesus monkeys were treated with the
VP35 PMO only (n ¼ 4) or a combination of the VP24, VP35,
and L PMOs (n¼4) from 2 d prior to EBOV infection through
day 9 of the infection (Figure 6A). An initial study tested the
efﬁcacy of the VP35 PMO, the compound that exhibited the
highest activity in mice. Unfortunately, all of the VP35 PMO-
treated monkeys, as well as the untreated control monkey,
died within the time-to-death expected for EBOV-infected
rhesus macaques (days 7, 7, 8, 8, and 7, respectively). In
contrast, treatment of rhesus macaques with a combination of
the VP24, VP35, and L PMOs showed substantial efﬁcacy. Two
PMO-treated monkeys survived the EBOV challenge with few
clinical signs beyond mild depression from days 6–9 (Figure
6B). A third PMO-treated monkey cleared the EBOV
infection and remained aviremic from days 9–14 (Figure
6C), but died of a severe bacterial infection, with no evidence
of ongoing EBOV infection, on day 16 (Figure 6B, unpub-
lished data). The fourth PMO-treated monkey succumbed to
EBOV infection on day 10 (Figure 6B). Three naı ¨ve control
monkeys used in this experiment received no treatment and
succumbed to EBOV infection on days 7, 9, and 10. Since the
VP35 PMO alone did not provide any protection to nonhu-
man primates, these data suggest that a combination of PMOs
is more efﬁcacious than a single-target PMO treatment and
also suggests that protection in the combination PMO-
treated monkeys is not due to nonspeciﬁc effects of PMO
administration.
We were able to identify only a few early clinical signs or
laboratory values that correlated with survival. The labora-
tory tests that most closely predicted survival were viral titers,
platelet counts, and liver-associated enzymes in the blood.
The monkeys that did not survive infection had detectable
virus by day 5, in stark contrast to the PMO-treated monkeys
that survived, which had little to no detectable viremia on
days 3–14 (Figure 6C). Both the PMO-treated and naı ¨ve
monkeys exhibited thrombocytopenia, although the PMO-
Figure 2. Ebola-Specific PMOs Protect Mice from Lethal Ebola Virus Infection
(A–C) Survival of mice (n ¼10) pretreated at 4 h and 24 h before EBOV infection with 500 (square) or 50 (triangle) lg doses of PMOs targeting EBOV-
(filled) or MARV-specific (unfilled) VP24 (A), VP35 (B), L (C), or with PBS (3).
(D) Survival of mice (n ¼ 10) pretreated at 24 h and 4 h before EBOV infection with 500 lg (square), 50 lg (triangle), or 5 lg (circle) doses of a
combination of the EBOV- (filled) or MARV-specific (unfilled) VP24, VP35, and L PMOs or PBS (3).
(E) Survival of mice (n¼10) treated 4 h before (unfilled) or 24 h after (filled) EBOV infection with 500 lg (square), 50 lg (triangle), or 5 lg (circle) of the
combination of EBOV-specific PMOs or an unrelated sequence (3). All the animals in these studies were monitored for at least 28 d for illness, and there
were no differences observed in survival within any of the groups between 14 d and 28 d.
DOI: 10.1371/journal.ppat.0020001.g002
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much below 100,000 at any time (Figure 6D). Similarly, all the
monkeys experienced increases in their liver-associated
enzyme levels, including alkaline phosphatase. However, the
levels in the surviving monkeys did not climb as high as those
that succumbed to the infection and returned to normal
levels within the month after the EBOV infection (Figure 6E,
unpublished data).
No correlation was found between survival and multiple
other hematological values, body temperature, serum cyto-
kines (measured by a Human 25-plex kit from Biosource,
Camarillo, California, United States), or ﬁbrin degradation
products (unpublished data). Importantly, PMO administra-
tion did not induce early (0–2 dpi) detectable serum IFN,
TNF, or other cytokines in the nonhuman primates (unpub-
lished data), indicating that the protection was likely not due
to nonspeciﬁc effects via induction of innate immunity. Since
the surviving PMO-treated monkeys had low to undetectable
viremias following infection, we assessed the immune
responses of the surviving monkeys. By 28 d after EBOV
challenge, the surviving rhesus monkeys had high levels of
both anti-EBOV antibodies and T cell responses, similar to
the PMO-protected mice (unpublished data).
Figure 3. PMO Treatment Slows Viral Replication in Mice
(A–D) C57BL/6 mice were challenged intraperitoneally with 1,000 plaque-
forming units of EBOV following treatment with PMOs. Immunoperox-
idase stain showing presence of viral antigen is brown with hematoxylin
counterstain. Spleen (1003) of a mouse treated with scrambled PMO (A)
or the EBOV VP24, VP35, and L PMOs (B) 3 d after EBOV infection. Diffuse
staining pattern in the livers (6003) of the scrambled PMO-treated mice
(C) on day 6 of EBOV infection, compared with focal areas of infection in
the mice treated with the combination of PMOs (D).
(E) Viral titers in tissues from mice treated with a combination of 3 PMO
and infected with 1,000 pfu of EBOV. Samples of the liver, spleen, and
kidney were taken at 3 d or 6 d post challenge (dpc), macerated, and
analyzed for viral titer using plaque assay. The data are presented as the
mean viral titer of three mice with errors bars representing the standard
deviation.
DOI: 10.1371/journal.ppat.0020001.g003
Figure 4. Immune Responses of PMO-Treated Mice Following Survival of
Ebola Virus Infection
(A) PMO-treated C57BL/6 mice that have previously survived EBOV
infection generate EBOV-specific CD8
þ responses. Pooled splenocytes
from three PMO-treated EBOV survivors were restimulated in vitro with
EBOV-specific VP35 or NP peptides, an irrelevant Lassa NP peptide as a
negative control, or PMA/ionomycin as a positive control. The stimulated
cells were stained after for 4 h in culture with anti-CD44-FITC, anti-IFN-c-
PE, and anti-CD8-Cy-Chrome. The percent of CD44
þ, IFN-cþ cells among
CD8
þ lymphocytes is indicated in the upper right quadrant of each plot.
These data are representative of several experiments examining the
EBOV-specific T cell epitopes in PMO-treated mice after challenge.
(B) Total serum anti-EBOV antibodies were measured in surviving mice
prior to or 4 wk following treatment and challenge. PMO mice were
treated with the combination of PMOs 24 hand 4 h before challenge, and
their antibody responses are compared with mice treated with Ebola
VLPs 24 h before EBOV infection. The results are depicted as the
endpoint titers of the individual mice (filled circles). The horizontal line in
each column represents the geometric mean titer of the group.
(C) Mice that previously survived EBOV challenge following PMO
treatment were rechallenged with 1,000 pfu of mouse-adapted Ebola
virus4 wk afterthe initialchallenge. Resultsareplottedas percent survival
forthePMO-treatedmice(black)andnaı ¨vecontrolmice(n¼10pergroup).
DOI: 10.1371/journal.ppat.0020001.g004
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EBOV infections represent a signiﬁcant public health
threat, with no reliable effective chemotherapeutics. Our
current studies indicate the effectiveness of PMOs targeted to
speciﬁc EBOV mRNAs against in vitro, rodent, and nonhu-
man primate EBOV infections. The data presented here are
in line with our working hypothesis that a combination of
PMOs that target multiple viral genes can slow EBOV
replication, allowing enough time for development of
antiviral immune responses and viral clearance.
Cell-free experiments demonstrated that the EBOV-specif-
ic PMOs were efﬁcient at inhibiting EBOV mRNA translation
and that MARV-speciﬁc PMOs had no effect on translation of
corresponding EBOV genes. While the reporter-based in
vitro assays appeared to be good indicators of sequence-
speciﬁc activity of PMOs, it seems that in the case of EBOV,
the in vitro translation assays were not fully predictive of the
rodent efﬁcacy data. Using VeroE6 cells we showed that
EBOV replication was moderately suppressed in cells treated
with EBOV-speciﬁc PMOs. However, no visible difference was
observed when comparing the ability of a single PMO and the
combination of three PMOs to reduce viral growth. The
PMOs used in these studies were not conjugated with
peptides that facilitate cellular uptake. We have observed
lower cellular uptake of naked PMOs compared with peptide-
conjugated PMOs by Vero E6 cells (unpublished data), and
this may explain the moderate inhibition observed in the in
vitro replication assay. Nonetheless, the data summarized in
Figure 1 clearly indicate the feasibility of speciﬁc gene
targeting by unconjugated PMO and the favorable antiviral
activity of these compounds.
Here, we have presented data demonstrating a therapeutic
intervention that interferes with viral replication. We
hypothesize that the efﬁcacy of this strategy relies on the
ability of PMOs, by reducing viral replication, to create a
window of opportunity for the immune system to clear the
otherwise lethal infection. This approach does not result in
sterile protection, as evidenced by the robust anti-EBOV
immune responses in the surviving mice and nonhuman
primates, and by the mild clinical signs (thrombocytopenia,
liver enzyme elevations, depression, and lethargy) observed in
the PMO-treated monkeys. It is likely that successful treat-
ment of patients infected with EBOV will require a multi-
faceted approach consisting of an antiviral, and therapeutics
for symptom and disease management [1,9].
Post-exposure treatment with PMOs was the most efﬁca-
cious against EBOV in rodents, and, presumably, this is
explained by the pharmacokinetic properties of PMO.
Following parenteral injection, PMOs are cleared from the
bloodstream within hours, but accumulate and remain within
tissues such as spleen and liver for days (unpublished data). By
administering PMO after challenge, it is likely that higher
concentrations were available in the circulation and tissues
during the peak of viral replication. Thus, the PMOs may have
been able to reduce ampliﬁcation of EBOV during this
critical timeframe, allowing development of appropriate host
immune responses to the otherwise lethal viral infection [27–
29]. Since effective treatment seemed to require critical
timing of PMO administration, and nonhuman primates are
highly sensitive to EBOV infection, we decided to both
pretreat and administer daily doses of PMOs after viral
challenge in the proof-of-concept nonhuman primate stud-
ies. While short-term stability in vivo is an unfavorable
property for a potential therapeutic, it should be noted that
for a deadly acute infection that has only a short period of
treatment in the clinic, repeated administration of a life-
saving drug is entirely feasible. Along these lines, future
studies may show that the pharmacokinetics of PMO can be
enhanced by other modiﬁcations or alternative routes of
administration or regimen to improve efﬁcacy.
Inordertocorroboratetheinvitrodataandnarrowdownthe
number of antiviral lead candidates, the EBOV mouse model
was anobviouschoicefortestingmultiplecandidatePMOs [30].
While the mouse model has several differences in pathogenesis
compared with EBOV infection of nonhuman primates and
humans [31–33], it is widely accepted as an appropriate model
for rapid testing of potential antivirals before proceeding to
NHP trials. While the differences in the pathology may severely
hamper the predictive value of mouse studiesusing therapeutic
strategies that rely on targeting mouse-speciﬁc virus–host
interactionorthepathologicresponsebyrodents,interventions
that target viral replication can be evaluated with a high degree
of conﬁdence in this model. Antiviral efﬁcacy in rodents may
not always be predictive of efﬁcacy in nonhuman primates,
although an antiviral compound that is unsuccessful in rodents
willmost likelyalsofailinnonhuman primates, justifyinginitial
screening in rodent models.
We have initiated a drug-discovery strategy to identify
‘‘druggable,’’ efﬁcacious anti-ﬁlovirus PMOs. This proof-of-
principle study using PMOs demonstrates favorable anti-
EBOV activity both in vitro and in vivo; thus, these molecules
Figure 5. Treatment of Guinea Pigs with Antisense PMOs Increases
Survival Following Lethal Ebola Virus Infection
Hartley guinea pigs (n ¼ 6) weighing 400–500 g each were treated
intraperitoneally with 10 mg each of VP24, VP35, and L PMO in PBS at
 24 (triangle), þ24 (circle), or þ96 (square) h post challenge. Control
guinea pigs were injected with PBS only (diamond). The guinea pigs
were infected subcutaneously with ;1,000 pfu of EBOV and monitored
for illness for 21 d.
(A) The data are presented as percent survival for each group.
(B) Viral titers in the serum of guinea pigs at 7 d post challenge (dpc). The
data are presented as the titers of individual guinea pigs treated with
PMOs at  24, þ24, or þ96 h post challenge or PBS only and the mean
viral titer for each group (horizontal line). Animals which survived are
represented by open symbols and those that succumbed to disease are
represented by filled symbols.
DOI: 10.1371/journal.ppat.0020001.g005
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evaluation and optimization. Future studies will focus on
determining the most favorable PMO dose and regimen and
also the therapeutic potential of these molecules. Addition-
ally, antisense PMO designed to target other regions within
the EBOV genome will be pursued. Genetically designed
microbial therapeutics, such as antisense PMOs or other
sequence-based approaches, allow quick hit-to-lead optimi-
zation and may accelerate time-to-drug development. To-
gether, these strategies could result in a highly efﬁcacious
therapeutic treatment regimen for lethal viral infections.
Nucleotide-based antivirals, such as PMOs, can be easily
produced in large quantities, have already been tested in
human clinical trials, and have appropriate safety proﬁles for
use with humans [34]. The results presented here have far-
reaching implications for the treatment of highly lethal
hemorrhagic fever viruses, and for diseases caused by many
other acute viral diseases including SARS, inﬂuenza, and
dengue, or other emerging pathogens.
Materials and Methods
PMOs. PMOs were designed with sequence homology near or
overlapping the AUG translational start site of EBOV VP35 (59-
CCTGCCCTTTGTTCTAGTTG-39), EBOV VP24 (59-
GCCATGGTTTTTTCTCAGG-39), and EBOV L (59-
TGGGTATGTTGTGTAGCCAT-39). Similarly, PMOs were designed
with sequence homology near or overlapping the AUG start site of
MARV VP35 (59-GTCCCACATTGTGAAAATTAT-39), MARV VP24
(59-CGTTGATAATTCTGCCATG-39), and MARV L (59-GATATT
GAGTTGGATGCTGCAT-39). Either the MARV-speciﬁc PMOs or an
unrelated, ‘‘scrambled’’ PMO (59-AGTCTCGACTTGCTACCTCA-39)
were used as controls in these experiments. The PMOs were
synthesized by AVI BioPharma, (Corvallis, Oregon, United States),
as previously described [35].
In vitro translation assay. The protein coding sequence for ﬁreﬂy
luciferase, without the initiator-Met codon ATG, was subcloned into
the multiple cloning site of plasmid pCiNeo (Promega, Madison,
Wisconsin, United States). Subsequently, complementary oligonucleo-
tides for EBOV VP35 ( 98 to þ39; bases 3020 to 3157), EBOV VP24
( 84 toþ43; bases 10261 to 10390), EBOV L ( 80 toþ49; bases 11501 to
11632) were duplexed and subcloned into Nhe 1 and Sal 1 sites. The
single AUG in each viral sequence leader is in frame with the coding
sequence of luciferase. The plasmids were linearized with Not I, and in
Figure 6. Treatment of Rhesus Macaques with Antisense PMOs Provide Protection against Lethal Ebola Virus Infection
(A) Treatment schedule for proof-of-concept trial using PMO to treat lethal Ebola virus infection in nonhuman primates.
(B) Survival following infection with 1,000 pfu of EBOV in monkeys treated with a combination of PMOs ( &, n¼4) or untreated monkeys (*, n¼3). The
arrows indicate the time of death of each PMO-treated monkey.
(C–E) Viral titers (C), platelet counts (D), or alkaline phosphatase levels (E) in the blood of the PMO-treated monkeys [0646 (¤), 1438 (m), 1496 (3), 1510
(&)] or a representative untreated monkey (*).
DOI: 10.1371/journal.ppat.0020001.g006
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Megascript kit and protocol (Ambion,Austin, Texas, United States). In
vitro translations were carried out by programming reactions with
transcribed RNA at a ﬁnal concentration of 1 nM, as previously
described[36].The averagelight units producedby theset of reactions
for each treatment were normalized to the mean of all water-only
control reactions and expressed as relative light units as compared to
the luciferase signal of control reactions.
In vitro assessment of viral replication in the presence of PMOs.
Vero E6 cells were grown to conﬂuency in a 24-well plate. On day 0,
the indicated PMOs were added in 100 ll of serum-free EMEM. After
2 h, 900 ll of EMEM containing 10% fetal calf serum was added for a
ﬁnal concentration of 20 lM of the VP24, VP35, L, or a combination
of all three PMOs. On day 1, the medium was removed from the cells
and one multiplicity of infection of EBOV-Zaire was added to each
well in 100 ll of serum-free EMEM. After 1 h, the viral inoculum was
removed and the cells washed twice with PBS. The PMOs were
reintroduced for 2 hs in serum-free EMEM and then brought up to a
total of 1 ml with EMEM containing 10% fetal calf serum.
Supernatant was removed from the cells at 24, 48, or 72 hpi, and
the viral titers were determined by standard plaque assay [37].
Animals. C57BL/6 mice, aged 8–10 wk, of both sexes, were obtained
from the National Cancer Institute, Frederick Cancer Research and
Development Center (Frederick, Maryland, United States). Mice were
housed in microisolator cages and provided autoclaved water and
chow ad libitum. Mice were challenged by intraperitoneal injection
with ;1,000 pfu of mouse-adapted EBOV diluted in phosphate
buffered saline (PBS) [30]. Unless otherwise noted, mice were treated
23at 24 h and 4 h prior to EBOV challenge with 0.5 mg, 0.05, or 0.005
mg of each of the EBOV or MARV VP24, VP35, and L PMOs, a
combination of PMOs, or an unrelated PMO. In one presented study,
the PMOs (0.5, 0.05, or 0.005 mg) were administered in a single dose 4
h before or 24 h after challenge. Previously, we showed Ebola virus-
like particles given 24 h before viral challenge protects mice from
lethal EBOV infection. Therefore, for comparison of post-challenge
immune responses, a group of mice was injected with virus-like
particles 24 h before EBOV challenge [15]. C57BL/6 mice were
challenged intraperitoneally with 1,000 plaque-forming units of
mouse-adapted EBOV [30].
Female Hartley guinea pigs, 400–500 g in weight, were obtained
from Charles River Laboratories (Wilmington, Massachusetts, United
States) and quarantined at the US Army Research Institute for
Infectious Diseases for at least 72 h before manipulations. To
determine efﬁcacy of the PMOs in guinea pigs, the animals were
treated intraperitoneally with a single 10-mg dose of each of the VP24,
VP35, and L PMOs 24 h before or 24 h or 96 h after subcutaneous
challenge with 1,000 pfu of guinea-pig adapted EBOV [38]. On day 7,
the guinea pigs were bled from the retro-orbital sinus and the plasma
samples were assessed for viral titers by plaque assay [37].
Female rhesus macaques of 3–4 kg in weight were challenged with
;1,000 pfu of EBOV-Zaire (1995 strain) [14] by intramuscular
injection following PMO treatment. The monkeys were treated from
days  2 through day 9 via a combination of parenteral routes (for
treatment schedule, see Figure 6). The dose of the VP24 PMO was
12.5–25 mg at each injection, and the dose of the VP35 and L PMOs
ranged from 12.5–100 mg per injection. All the monkeys in this study
were found to be STLV-1, SIV-, and Herpes B-negative in testing prior
to initiation of the study. Monkeys 1496 and 1510 both presented with
redness in and bleeding from their vaginal area on days 3–5 post
infection. The estrus status of the other monkeys in this study was
unknown, although they did not present with vaginal bleeding
throughout the 35 d that they were monitored during this study.
The number of animals in each group was determined with the help
ofa statisticianin orderto use theleast number ofanimalspossibleyet
still to have the statistical power necessary to allow meaningful
interpretation of the data produced. All EBOV-infected animals were
handled under maximum containment in a biosafety–level-4 labo-
ratory at the US Army Medical Research Institute for Infectious
Diseases. Research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adhered to principles
stated in the National Research Council’s Guide for the Care and Use of
Laboratory Animals (1996). The facility where this research was
conducted is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Hematologic and pathologic sampling. Blood samples were
obtained under anesthesia by cardiac puncture for mice and from
the femoral vein of monkeys. Viremia was assayed by traditional
plaque assay [37]. Hematological, cytokine, and D dimer levels, as well
as liver-associated enzymes, were measured as previously described
[16]. On day 3 and day 6 after EBOV infection, gross necropsies were
performed on three mice from each group pretreated with either the
combination of PMOs or the ‘‘scrambled’’ PMO. The tissues were
collected in 10% neutral buffered formalin and held in the biosafety–
level-4 laboratory for a minimum of 30 d. The tissues were then
decontaminated, embedded in parafﬁn, and sectioned for histology.
The sections were then stained with hematoxylin and eosin for
routine light microscopy or exposed to EBOV-speciﬁc antisera to
identify viral antigen within the tissue samples.
Immune responses following EBOV infection. Blood was collected
from the surviving mice or monkeys, respectively, 28 d after EBOV
challenge. Levels of EBOV-speciﬁc antibodies were determined from
serum or plasma samples, as previously described [39]. Antibody titers
were deﬁned as the reciprocal of the highest dilution giving a net
optical density value  0.2. Epitopes recognized by CD4
þ and CD8
þ T
cells of surviving mice were determined as previously described [40].
Brieﬂy, EBOV-speciﬁc responses were analyzed by culturing spleno-
cytes with 1–5 lg overlapping 15-residue peptides representing the
GP or VP40 of EBOV (Mimotopes, Clayton, Victoria, Australia) or 25
ng/ml phorbol 12-myristate 13-acetate and 1.25 lg/ml ionomycin in
complete RPMI containing 10 lg/ml brefeldin A. After 5 h of culture,
the cells were stained with anti-CD44, -CD8, or -CD4 (Pharmingen,
San Diego, California, United States) in brefeldin A. After the cell
surface staining, the cells were ﬁxed in 1% formaldehyde, permea-
bilized with saponin, and stained with anti-IFN-c PE (Pharmingen).
Statistical analysis. To compare the survival rates in the rodent
experiments, we used a Fisher exact test with stepdown bootstrap
adjustment. In the guinea pig experiments, the viral titers were
analyzed by ANOVA with post hoc Dunnett’s test, and the effect of
viral titers on survival were analyzed by logistic regression. A p value
of  0.05 was considered signiﬁcant.
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